2026-06-14T03:52:23Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/147462025-04-07T13:06:11Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19608

00925njm 22002777a 4500 dc Pérez-Latorre, Leire author Berenguer, Juan author Micán, Rafael author Montero, Marta author Cifuentes, Carmen author Puig, Teresa author Sanz, José author Ferrero, Oscar L author de la Fuente, Belén author Rodríguez, Carmen author Reus, Sergio author Hernández-Quero, José author Gaspar, Gabriel author Pérez-Martínez, Laura author García, Coral author Force, Luis author Veloso, Sergio author De Miguel, Marta author Jarrin Vera, Inmaculada author González-García, Juan author GeSIDA 8514 Study Group author 2021-06 Background: Recent and reliable estimates on the prevalence of coinfection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) in Europe are lacking.AimLeveraged on a study designed to assess HIV/HCV coinfection prevalence, we assessed the prevalence of HIV/HBV coinfection in Spain in 2018 and compared the results with five similar studies performed since 2002. Methods: This cross-sectional prevalence study was carried out in 43 centres, and patients were selected using simple random sampling. The reference population comprised 40,322 patients and the sample size were 1,690 patients.ResultsThe prevalence of HIV/HBV coinfection in Spain at the end of 2018 was 3.2%. The prevalence in 2002, 2009, 2015, 2016 and 2017 was 4.9%, 3.4%, 3%, 3.9% and 3%, respectively. Among the HIV/HBV-coinfected patients identified in 2018, 16.7% had cirrhosis according to transient elastography and 26.3% tested positive for antibodies against hepatitis D virus. All HIV/HBV-coinfected patients were receiving drugs with activity against HBV, and 97% of those tested for HBV DNA had an HBV DNA load < 80 IU/mL. Conclusions: The prevalence of HIV/HBV coinfection in Spain remained stable at around 3% for a decade. Our data could facilitate the design of national programmes to control HBV infection and help identify areas of patient management that need improvement. Euro Surveill. 2021 Jun;26(25):2000236. 10.2807/1560-7917.ES.2021.26.25.2000236 1560-7917 Euro Surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 34169818 http://hdl.handle.net/20.500.12105/14746 HBV therapy HIV/HBV coinfection Hepatitis delta virus HIV/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018